Stock Insights: Walt Disney, Seattle Genetics, Express Scripts, Thompson Creek, Tempur Pedic May 9th

Walt Disney Co. (NYSE:DIS): RBC Capital increased its target on Disney, as it expects the success of the company’s The Avengers film to lead to strong sequels, and increase the momentum of other Disney action movies and character franchises. The firm maintains an Outperform rating on the stock.

Seattle Genetics Inc. (NASDAQ:SGEN): After Seattle Genetics reported weaker than expected Q1 Adcetris sales, RBC Capital still believes that the company has multiple market expansion opportunities. The firm thinks that the company could announce new data at ASCO that will provide a positive catalyst for the stock, and it maintains an Outperform rating on the shares.

Express Scripts Inc. (NASDAQ:ESRX): JPMorgan believes the recent volatility in shares of Express Scripts has created a buying opportunity ahead of the company’s Q1 results on May 10. The firm attributes the pullback to concerns around guidance and the 2013 selling season.

Thompson Creek Metals Company Inc. (NYSE:TC): JPMorgan thinks shares of Thompson Creek are pricing in operational issues at Mt. Milligan and metal price levels that are unlikely to occur. The firm lowered its price target for shares to $9.50 from $11.50, but keeps an Overweight rating on the stock.

Tempur Pedic International Inc. (NYSE:TPX): Oppenheimer views the decline in Tempur-Pedic since the company announced its Q1 results as an overreaction. After speaking with the company’s management, the firm views Tempur-Pedic’s decision to discount its Cloud Supreme mattress as a less dramatic strategy shift than the drop in the stock suggests. The firm lowered its target on the shares to $75 from $90 but reiterates an Outperform rating.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.